Denteric’s executive team CEO Sean McLoughlin, COO Larisa Chisholm and CSO Paul Cockle will be at the World Vaccine Congress Washington from 30 March – 2nd April We look forward to connecting with those interested in learning more about GPV381
Our focus is on tackling upstream drivers of chronic inflammation through a disease-modifying therapeutic vaccine approach, beginning with periodontitis and its broader systemic implications.
With important clinical milestones ahead, we’re entering a year of focused execution and value inflection.